New direction for glaucoma therapeutics: Focus on the olfactomedin domain of myocilin

Future Medicinal Chemistry

Volumn 4, Issue 17, 2012, Pages 2131-2134

  Donegan, Rebecca K ^a   Lieberman, Raquel L ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

chaperone; glaucoma; myocilin; olfactomedin; protein aggregation

Indexed keywords

ANTIGLAUCOMA AGENT; COPPER ZINC SUPEROXIDE DISMUTASE; FLAVONOID; MYOCILIN; POLYPHENOL DERIVATIVE; PROTEIN P53;

CELL MIGRATION; CELL STRESS; ENDOPLASMIC RETICULUM; GENE MUTATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OLFACTOMEDIN; OPEN ANGLE GLAUCOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SECRETION; REVIEW; TRABECULAR MESHWORK;

CYTOSKELETAL PROTEINS; EXTRACELLULAR MATRIX PROTEINS; EYE; EYE PROTEINS; GLAUCOMA; GLYCOPROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN STRUCTURE, TERTIARY;

EID: 84870403801     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.132     Document Type: Review

References (28)

1. Alward WL. Medical management of glaucoma. N. Engl. J. Med. 339(18), 1298-1307 (1998).
2. Quigley HA. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80(5), 389-393 (1996).
3. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N. Engl. J. Med. 360(11), 1113-1124 (2009).
4. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat. Rev. Drug Discov. 11(7), 541-559 (2012).
5. Gong G, Kosoko-Lasaki O, Haynatzki GR, Wilson MR. Genetic dissection of myocilin glaucoma. Hum. Mol. Genet. 13, R91-R102 (2004).
6. Resch Z, Fautsch M. Glaucoma-associated myocilin: a better understanding but much more to learn. Exp. Eye Res. 88(8), 704-712 (2009).
7. Zode GS, Kuehn MH, Nishimura DY et al. Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. J. Clin. Invest. 121(9), 3542-3553 (2011).
8. Liu Y, Vollrath D. Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma. Hum. Mol. Genet. 13(11), 1193-1204 (2004).
9. Lam DS, Leung YF, Chua JK et al. Truncations in the TIGR gene in individuals with and without primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 41(6), 1386-1391 (2000).
10. Kim BS, Savinova OV, Reedy MV et al. Targeted disruption of the myocilin gene (myoc) suggests that human glaucoma-causing mutations are gain of function. Mol. Cell. Biol. 21(22), 7707-7713 (2001).
11. Gobeil S, Rodrigue M-A, Moisan S et al. Intracellular sequestration of hetero-oligomers formed by wild-type and glaucoma-causing myocilin mutants. Invest. Ophthalmol. Vis. Sci. 45(10), 3560-3567 (2004).
12. Nakano M, Ikeda Y, Taniguchi T et al. Three susceptible loci associated with primary open-angle glaucoma identified by genome-wide association study in a Japanese population. Proc. Natl Acad. Sci. USA 106(31), 12838-12842 (2009).
13. Polansky JR, Fauss DJ, Chen P et al. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica 211(3), 126-139 (1997).
14. Vollrath D, Liu Y. Temperature sensitive secretion of mutant myocilins. Exp. Eye Res. 82(6), 1030-1036 (2006).
15. Gobeil S, Letartre L, Raymond V. Functional analysis of the glaucoma-causing TIGR/myocilin protein: integrity of amino-terminal coiled-coil regions and olfactomedin homology domain is essential for extracellular adhesion and secretion. Exp. Eye Res. 82(6), 1017-1029 (2006).
16. Burns JN, Turnage KC, Walker CA, Lieberman RL. The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder. Biochemistry 50(26), 5824-5833 (2011).
17. Burns JN, Orwig SD, Harris JL, Watkins JD, Vollrath D, Lieberman RL. Rescue of glaucoma-causing mutant myocilin thermal stability by chemical chaperones. ACS Chem. Biol. 5(5), 477-487 (2010).
18. Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation. Nat. Rev. Mol. Cell Biol. 9(12), 944-957 (2008).
19. Orwig SD, Perry CW, Kim LY et al. Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin. J. Mol. Biol. 421, 242-255 (2012).
20. Sacca SC, Bolognesi C, Battistella A, Bagnis A, Izzotti A. Gene-environment interactions in ocular diseases. Mutat. Res. 667(1-2), 98-117 (2009).
21. Ghanem AA, Arafa LF, El-Baz A. Oxidative stress markers in patients with primary open-angle glaucoma. Curr. Eye Res. 35(4), 295-301 (2010).
22. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5(11), 821-837 (2004).
23. Yam GH-F, Gaplovska-Kysela K, Zuber C, Roth J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest. Ophthalmol. Vis. Sci. 48(4), 1683-1690 (2007).
24. Zode GS, Bugge KE, Mohan K et al. Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 53(3), 1557-1565 (2012).
25. Jia L-Y, Gong B, Pang C-P et al. Correction of the disease phenotype of myocilin-causing glaucoma by a natural osmolyte. Invest. Ophthalmol. Vis. Sci. 50(8), 3743-3749 (2009).
26. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 18(1), 64-76 (2012).
27. Holdgate GA, Anderson M, Edfeldt F, Geschwindner S. Affinity-based, biophysical methods to detect and analyze ligand binding to recombinant proteins: matching high information content with high throughput. J. Struct. Biol. 172(1), 142-157 (2010).
28. Tomarev SI, Nakaya N. Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology. Mol. Neurobiol. 40(2), 122-138 (2009).